H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report) on September 9 and set a price target of $210.00. The company’s shares closed last Friday at $62.07.
Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Aeterna Zentaris, and Regulus. According to TipRanks, Selvaraju has an average return of -28.2% and a 23.37% success rate on recommended stocks.
In addition to H.C. Wainwright, Axsome Therapeutics also received a Buy from Mizuho Securities’s Graig Suvannavejh in a report issued on September 7. However, on August 30, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).
AXSM market cap is currently $2.5B and has a P/E ratio of -15.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Zymeworks (ZYME) Receives a Buy from SVB Securities
- SVB Securities Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
- Analysts’ Top Utilities Picks: Devon Energy (DVN), CMS Energy (CMS)
- SVB Securities Keeps Their Buy Rating on MannKind (MNKD)
- SVB Securities Sticks to Its Hold Rating for Illumina (ILMN)